UTC Bid to Delay Launch of Liquidia’s Yutrepia Shot Down (3)

A federal judge dismissed United Therapeutics Corp.'s cross-claims against Liquidia Corp. and the US Food and Drug Administration, allowing Liquidia’s lung-disease drug Yutrepia to move forward for a launch as early as this month.

Judge Timothy J. Kelly’s order, issued Friday in the US District Court for the District of Columbia, means Liquidia’s Yutrepia can receive final approval and launch when UTC’s exclusivity for the dry-powder-inhalation version of its blockbuster Tyvaso expires May 23.

The FDA declined to comment. UTC and Liquidia didn’t immediately respond to requests for comment.

Shares of Liquidia rose by as much as 17%, the ...